| scholarly article | Q13442814 |
| P356 | DOI | 10.3810/PGM.2010.11.2226 |
| P953 | full work available at URL | http://www.tandfonline.com/doi/pdf/10.3810/pgm.2010.11.2226 |
| P698 | PubMed publication ID | 21084785 |
| P2093 | author name string | Howard S. Smith | |
| Roy D. Altman | |||
| P2860 | cites work | Lidocaine patch 5% and its positive impact on pain qualities in osteoarthritis: results of a pilot 2-week, open-label study using the Neuropathic Pain Scale | Q48823796 |
| Risk of road traffic accidents associated with the prescription of drugs: a registry-based cohort study | Q50086674 | ||
| Lidocaine patch treatment in patients with low back pain: results of an open-label, nonrandomized pilot study. | Q51217024 | ||
| Aquatic physical therapy for hip and knee osteoarthritis: results of a single-blind randomized controlled trial. | Q53215431 | ||
| Assessing chronic joint pain: Lessons from a focus group study | Q57915736 | ||
| Withdrawal of Analgesic Medication for Chronic Low-Back Pain Patients | Q60729099 | ||
| Relative respiratory depresant effects of oxymorphone (numorphan) and morphine | Q79151631 | ||
| Pharmacological management of persistent pain in older persons | Q84159023 | ||
| Gastrointestinal safety of nonsteroidal antiinflammatory drugs and selective cyclooxygenase-2 inhibitors in patients on warfarin | Q43266149 | ||
| Diclofenac sodium gel in patients with primary hand osteoarthritis: a randomized, double-blind, placebo-controlled trial | Q43300193 | ||
| Increased plasma morphine metabolites in terminally ill cancer patients with delirium: an intra-individual comparison | Q43886110 | ||
| Abuse liability in opioid therapy for pain treatment in patients with an addiction history | Q44246893 | ||
| A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain | Q44333586 | ||
| Psychiatric and pain characteristics of prescription drug abusers entering drug rehabilitation | Q44334223 | ||
| Differences in magnitude and duration of opioid-induced respiratory depression and analgesia with fentanyl and sufentanil | Q44337467 | ||
| Acute opioid administration improves work-related exercise performance in patients with chronic back pain | Q44339163 | ||
| A longitudinal study of the efficacy of a comprehensive pain rehabilitation program with opioid withdrawal: comparison of treatment outcomes based on opioid use status at admission | Q44340204 | ||
| Functional outcomes in patients with chronic nonmalignant pain on long-term opioid therapy | Q44340392 | ||
| Opioid prescribing practices in chronic pain management: guidelines do not sufficiently influence clinical practice | Q44343386 | ||
| The association between opioid analgesics and unsafe driving actions preceding fatal crashes | Q44344442 | ||
| Polymorphism of mu-opioid receptor gene (OPRM1:c.118A>G) does not protect against opioid-induced respiratory depression despite reduced analgesic response. | Q44348189 | ||
| Opioid rotation from morphine to fentanyl in delirious cancer patients: an open-label trial | Q44349875 | ||
| A comparison of the efficacy and safety of nonsteroidal antiinflammatory agents versus acetaminophen in the treatment of osteoarthritis: a meta-analysis | Q45101921 | ||
| Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study | Q45209490 | ||
| Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways | Q45259355 | ||
| Morphine and outcomes in acute decompensated heart failure: an ADHERE analysis | Q45353975 | ||
| FDA focuses on drugs and liver damage: labeling and other changes for acetaminophen. | Q45923695 | ||
| Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis | Q46043948 | ||
| Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes | Q46056607 | ||
| The risk of motor vehicle accidents involving drivers with prescriptions for codeine or tramadol. | Q46091589 | ||
| Opiates should be avoided in acute decompensated heart failure | Q46113923 | ||
| Functionality and health-status benefits associated with reduction of osteoarthritis pain | Q46689129 | ||
| Primary care treatment of knee pain--a survey in older adults | Q46949477 | ||
| Effects of weight-bearing versus nonweight-bearing exercise on function, walking speed, and position sense in participants with knee osteoarthritis: a randomized controlled trial | Q47182165 | ||
| Exercise and weight loss in obese older adults with knee osteoarthritis: a preliminary study | Q47229833 | ||
| Two to five year follow-up of the LPM ceramic coated proximal interphalangeal joint arthroplasty | Q47855233 | ||
| Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluation | Q48726186 | ||
| Effectiveness of the lidocaine patch 5% on pain qualities in three chronic pain states: assessment with the Neuropathic Pain Scale | Q48823789 | ||
| Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials | Q24546221 | ||
| Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. | Q24547899 | ||
| Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study | Q28195282 | ||
| Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden | Q28209970 | ||
| Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib | Q28222097 | ||
| Opioid metabolism | Q28250437 | ||
| Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society | Q28251589 | ||
| Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II | Q28396036 | ||
| Trends in use of opioids for non-cancer pain conditions 2000-2005 in commercial and Medicaid insurance plans: the TROUP study. | Q30369899 | ||
| Opioids in chronic non-cancer pain: systematic review of efficacy and safety | Q31131499 | ||
| EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). | Q33260652 | ||
| OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines | Q33320085 | ||
| Oxymorphone extended release for the treatment of chronic low back pain: a retrospective pooled analysis of enriched-enrollment clinical trial data stratified according to age, sex, and prior opioid use. | Q33420120 | ||
| Increased prevalence of metabolic syndrome in individuals with osteoarthritis: an analysis of NHANES III data | Q33516685 | ||
| OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009. | Q33532831 | ||
| Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain | Q33705809 | ||
| Osteoarthritis of the hip or knee: which coexisting disorders are disabling? | Q33884900 | ||
| Will this patient develop persistent disabling low back pain? | Q34108771 | ||
| Systematic review: treatment agreements and urine drug testing to reduce opioid misuse in patients with chronic pain | Q34118245 | ||
| Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis | Q34165468 | ||
| The truth about pain management: the difference between a pain patient and an addicted patient | Q34499373 | ||
| Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial | Q34544702 | ||
| Exercise and dietary weight loss in overweight and obese older adults with knee osteoarthritis: the Arthritis, Diet, and Activity Promotion Trial | Q34547995 | ||
| Chapter 4. European guidelines for the management of chronic nonspecific low back pain. | Q34565815 | ||
| Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association | Q34576407 | ||
| The panorama of opioid-related cognitive dysfunction in patients with cancer: a critical literature appraisal | Q34580479 | ||
| Population-based surveillance for acute liver failure | Q34645492 | ||
| Acetaminophen hepatotoxicity and acute liver failure | Q34657996 | ||
| Within-subject comparison of the psychopharmacological profiles of oral hydrocodone and oxycodone combination products in non-drug-abusing volunteers | Q34913732 | ||
| Opioid therapy for nonspecific low back pain and the outcome of chronic work loss | Q34933400 | ||
| Relationship between pain and opioid analgesics on the development of delirium following hip fracture | Q35057460 | ||
| High tibial osteotomy for the treatment of osteoarthritis of the knee: a review of the literature and a meta-analysis of follow-up studies. | Q35163022 | ||
| Health-related quality of life in total hip and total knee arthroplasty. A qualitative and systematic review of the literature. | Q35760454 | ||
| Primary care provider concerns about management of chronic pain in community clinic populations | Q35901370 | ||
| Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials | Q35961855 | ||
| Survey of select practice behaviors by primary care physicians on the use of opioids for chronic pain | Q35962717 | ||
| Post-marketing experience with an opioid nasal spray for migraine: lessons for the future | Q36373556 | ||
| Pyrolytic carbon proximal interphalangeal joint arthroplasty: results with minimum two-year follow-up evaluation | Q36705640 | ||
| Special issues and concerns in the evaluation of older adults who have pain | Q37127958 | ||
| Trends in use of opioids by noncancer pain type 2000-2005 among Arkansas Medicaid and HealthCore enrollees: results from the TROUP study | Q37141254 | ||
| A long way to go: practice patterns and evidence in chronic low back pain care | Q37147281 | ||
| Abuse-deterrent opioid formulations: are they a pipe dream? | Q37154848 | ||
| The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers | Q37156564 | ||
| A review of the benefits and risks of nonsteroidal anti-inflammatory drugs in the management of mild-to-moderate osteoarthritis | Q37363371 | ||
| Opioids for chronic noncancer pain: prediction and identification of aberrant drug-related behaviors: a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline | Q37383814 | ||
| Nausea and vomiting side effects with opioid analgesics during treatment of chronic pain: mechanisms, implications, and management options | Q37419508 | ||
| Opioid switching and rotation in primary care: implementation and clinical utility | Q37550529 | ||
| Urine toxicology testing in chronic pain management | Q37566070 | ||
| Cost-effectiveness of interventions based on physical exercise in the treatment of various diseases: a systematic literature review | Q37618989 | ||
| Pharmacological therapies for osteoarthritis of the hand: a review of the evidence | Q37784485 | ||
| Safety and efficacy of topical diclofenac sodium 1% gel in knee osteoarthritis: a randomized controlled trial | Q39283052 | ||
| Titration with oxymorphone extended release to achieve effective long-term pain relief and improve tolerability in opioid-naive patients with moderate to severe pain | Q39312818 | ||
| Effective pain relief facilitates exercise therapy : Results of a multicenter study with controlled-release oxycodone in patients with movement pain | Q39314261 | ||
| Long-term use of controlled-release oxycodone for noncancer pain: results of a 3-year registry study | Q39336447 | ||
| A randomized, open-label study of once-a-day AVINZA (morphine sulfate extended-release capsules) versus twice-a-day OxyContin (oxycodone hydrochloride controlled-release tablets) for chronic low back pain: the extension phase of the ACTION trial. | Q39338999 | ||
| The ACTION study: a randomized, open-label, multicenter trial comparing once-a-day extended-release morphine sulfate capsules (AVINZA) to twice-a-day controlled-release oxycodone hydrochloride tablets (OxyContin) for the treatment of chronic, modera | Q39339189 | ||
| Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study | Q39342773 | ||
| Transdermal fentanyl versus sustained release oral morphine in strong-opioid naïve patients with chronic low back pain | Q39359254 | ||
| Safety, tolerability, and effectiveness of oxymorphone extended release for moderate to severe osteoarthritis pain: a one-year study | Q39369453 | ||
| Use of the lidocaine patch 5% in reducing intensity of various pain qualities reported by patients with low-back pain | Q39373636 | ||
| Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: a randomized controlled study | Q39379490 | ||
| Efficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: results from a randomized, placebo-controlled, double-blind trial and an open-label extension trial | Q39407383 | ||
| Comparison of the effectiveness and tolerability of lidocaine patch 5% versus celecoxib for osteoarthritis-related knee pain: post hoc analysis of a 12 week, prospective, randomized, active-controlled, open-label, parallel-group trial in adults | Q42610198 | ||
| Estimating attractiveness for abuse of a not-yet-marketed "abuse-deterrent" prescription opioid formulation | Q43225439 | ||
| Randomized controlled trial of diclofenac sodium gel in knee osteoarthritis | Q43236927 | ||
| Systemic bioavailability of topical diclofenac sodium gel 1% versus oral diclofenac sodium in healthy volunteers | Q43258644 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | osteoarthritis | Q62736 |
| opioid | Q427523 | ||
| chronic pain | Q1088113 | ||
| P304 | page(s) | 87-97 | |
| P577 | publication date | 2010-11-01 | |
| P1433 | published in | Postgraduate Medicine | Q7234297 |
| P1476 | title | Opioid therapy for osteoarthritis and chronic low back pain | |
| Opioid Therapy for Osteoarthritis and Chronic Low Back Pain | |||
| P478 | volume | 122 |
| Q38073084 | A review of pharmacotherapy for chronic low back pain with considerations for sports medicine |
| Q36071024 | Duloxetine in the management of chronic musculoskeletal pain |
| Q37115472 | Effectiveness and tolerability of tapentadol prolonged release compared with prior opioid therapy for the management of severe, chronic osteoarthritis pain |
| Q36709787 | Medical and psychological risks and consequences of long-term opioid therapy in women |
| Q38162664 | Using viscosupplementation to treat knee osteoarthritis |
Search more.